The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial

Molecular Psychiatry

Volumn 21, Issue 9, 2016, Pages 1225-1231

  Yatawara, C J ^a   Einfeld, S L ^a,b   Hickie, I B ^a   Davenport, T A ^a   Guastella, A J ^a  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NOSE SPRAY; OXYTOCIN; PLACEBO;

AGGRESSION; ARTICLE; AUTISM; AUTISM DIAGNOSTIC OBSERVATION SCHEDULE; BEHAVIOR ASSESSMENT; CAREGIVER; CAREGIVER BURDEN; CAREGIVER RATED SOCIAL RESPONSIVENESS SCALE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVELOPMENTAL BEHAVIOR CHECKLIST; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; HYPERACTIVITY; LEITER INTERNATIONAL PERFORMANCE SCALE REVISED; MALE; MICTURITION; MORNING DOSAGE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL INTERACTION; THIRST; TREATMENT DURATION; AUTISM SPECTRUM DISORDER; AUTISTIC DISORDER; HUMAN RELATION; INTRANASAL DRUG ADMINISTRATION; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; AUTISM SPECTRUM DISORDER; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; NASAL SPRAYS; OXYTOCIN; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84945558237     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.162     Document Type: Article

References (42)

1. Association AP. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. American Psychiatric Association: Washington DC, USA, 2000.
2. Autism Spectrum Disorders. Available at: http://www.cdc.gov/autism/ (last accessed date 20th November 2014).
3. Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Pediatr Health Care 2012; 26: 291-299.
4. Gibbs TT. Pharmacological treatment of autism. In: GJ Blatt (ed). The Neurochemical Basis of Autism. Springer: Boston, MA, USA, 2010, pp 245-267.
5. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 10: CD009260.
6. Howlin P, Baron-Cohen S, Hadwin J. Teaching Children with Autism to Mind-read: A Practical Guide. Wiley: New York, NY, USA, 1999.
7. Howlin P, Udwin O. Outcomes in Neurodevelopmental and Genetic Disorders. Cambridge University Press: Cambridge, MA, USA, 2002.
8. Guastella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: Evidence and future directions. Horm Behav 2012; 61: 410-418.
9. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 2008; 322: 900-904.
10. Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye-region of human faces. Biol Psychiatry 2008; 63: 3-5.
11. Schulze L, Lischke A, Greif J, Herpertz SC, Heinrichs M, Domes G. Oxytocin increases recognition of masked emotional faces. Psychoneuroendocrinology 2011; 36: 1378-1382.
12. Lischke A, Berger C, Prehn K, Heinrichs M, Herpertz SC, Domes G. Intranasal oxytocin enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroendocrinology 2012; 37: 475-481.
13. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 2005; 435: 673-676.
14. Guastella AJ, Hickie IB. Oxytocin treatment, circuitry and autism: a critical review of the literature placing oxytocin into the autism context. Biol Psychiatry 2015; pii: S0006-3223 (15) 00543-0.
15. Hollander E, Novotny S, Hanratty M, Yaffe R, Decaria CM. Oxytocin infusion reduces repetitive behaviours in adults with Autistic and Asperser's disorders. Neuropsychoparmacology 2003; 28: 193-198.
16. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007; 61: 498-503.
17. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2013; 38: 612-625.
18. Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Horm Behav 2010; 107: 4389-4394.
19. Anagnostou E, Soorya L, Chaplin W, Bartz JA, Halpern D, Wasserman S et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 2012; 3: 16.
20. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010; 67: 692-694.
21. Rogers SJ. Brief Report: early intervention in autism. J Autism Dev Disord 1996; 26: 243-246.
22. Harris SL, Handleman JS. Age and IQ at intake as predictors of placement for young children with autism: a four-to six-year follow-up. J Autism Dev Disord 2000; 30: 137-142.
23. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L et al. Austism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 1989; 19: 185-212.
24. Constantino JN. The Social Responsiveness Scale. Western Psychological Services: Los Angele, CA, USA, 2005.
25. Pine E, Luby J, Abbacchi A, Constantino JN. Quantitative assessment of autistic symptomatology in preschoolers. Autism 2006; 10: 344-352.
26. Einfeld S, Tonge B. The Developmental Behavior Checklist: the development and validation of an instrument to assess behavioral and emotional disturbance in children and adolescents with mental retardation. J Autism Dev Disord 1995; 25: 81-104.
27. Einfeld SL, Tonge BT. Manual for the Developmental Behaviour Checklist (Second Edition)-Primary Carer Version (DBC-P-P) and Teacher Version (DBC-P-T). Monash University Centre for Developmental Psychiatry and Psychology and School of Psychiatry, University of New South Wales: Melbourne and Sydney, Australia, 2002.
28. Roid GH, Miller LJ. Leiter International Performance Scare-Revised. Stoeling: Wooddale, IL, USA, 1997.
29. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 2000; 30: 237-243.
30. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disord 2006; 36: 863-870.
31. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration: Rockville, MD, USA, 1976.
32. Brannan AM, Heflinger CA. The Caregiver Strain Questionnaire: measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord 1997; 5: 212-223.
33. Cohen J. A power primer. Psychol Bull 1992; 112: 155-159.
34. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-19.
35. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, Balach L et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with 'treatment-resistant' major depression. J Am Acad Child Adolesc Psychiatry 1998; 37: 527-535.
36. King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr 2013; 167: 1045-1052.
37. Masi A, Amit L, Glozier N, Hickie IB, Guastella AJ. Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis. Transl Psychiatry 2015; 5: e640.
38. Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord 2013; 44: 521-531.
39. Guastella A, Gray K, Rinehart N, Alvares G, Tonge B, Hickie I et al. A randomized controlled trial of a course of intranasal oxytocin to treat youth diagnosed with autism. J Child Psychol Psychiatry 2015; 56: 444-452.
40. Miller G. The promise and perils of oxytocin. Science 2013; 339: 267-269.
41. Young LJ. When too much of a good thing is bad: chronic oxytocin, development, and social impairments. Biol Psychiatry 2013; 74: 160-161.
42. Chou C, DiGiovanni SR, Mejia R, Nielsen S, Knepper M. Oxytocin as an antidiuretic hormone. I. Concentration dependence of action. Am J Physiol 1995; 269: F70-F77.